Study of Nicotine Patches in Patients With Sarcoidosis

Status Completed

Clinical Trial Summary

The purpose of this study is to compare peoples with disease (sarcoidosis) to those without disease. We want to see if people with sarcoidosis have a different immune response to those people without disease. The goal of this study is to see if the nicotine patch is an anti-inflammatory treatment for sarcoidosis.

Clinical Trial Description

Until recently, there was no good explanation for the fact that smoking cigarettes actually reduces the risk of sarcoidosis. Research studies have shown that the nicotine, a common component of cigarette smoke, strongly suppresses the immune system and reduces the type of inflammation that is characteristic of sarcoidosis in the lungs. We propose that nicotine treatment, administered in the form of a skin patch, will reduce the severity of lung disease in patients with sarcoidosis. Sarcoidosis patients who volunteer to participate in this study will submit standardized questionnaires relating to their quality of life and the severity of their shortness of breath before and after treatment. We will also compare objective measures of lung function, radiographic parameters, and the severity of lung inflammation. We predict that nicotine treatment will reduce the severity of sarcoidosis symptoms, improve lung function, and resolve lung inflammation. If our hypothesis is proven to be correct in this relatively small group of patients, we will perform additional studies in a larger group of patients and will consider the features of sarcoidosis patients that predict a favorable response to nicotine and other nicotine-like drugs. If nicotine is ultimately found to be an effective treatment for sarcoidosis, it may replace some of the existing treatments which are frequently ineffective and have unacceptable side-effects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00701207
Study type	Interventional
Source	Ohio State University
Contact
Status	Completed
Phase	Early Phase 1
Start date	July 2008
Completion date	December 31, 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04064242` - Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	Phase 2
Terminated	`NCT00262132` - Mycophenolate for Pulmonary Sarcoidosis	Phase 3
Recruiting	`NCT05415137` - Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis	Phase 3
Recruiting	`NCT00001532` - Role of Genetic Factors in the Development of Lung Disease
Completed	`NCT04318392` - Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
Active, not recruiting	`NCT03755245` - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis	N/A
Completed	`NCT01587001` - The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis	N/A
Recruiting	`NCT05890729` - A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis	Phase 1/Phase 2
Recruiting	`NCT02824419` - Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis	Phase 2/Phase 3
Recruiting	`NCT06205121` - Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis	Phase 2
Completed	`NCT02200146` - Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).	Phase 3
Terminated	`NCT01732211` - A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis	Phase 2
Enrolling by invitation	`NCT06169397` - An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis	Phase 2
Active, not recruiting	`NCT05368883` - Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis	N/A
Not yet recruiting	`NCT05247554` - Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis	Phase 3
Completed	`NCT03599414` - CASPA: CArdiac Sarcoidosis in PApworth
Recruiting	`NCT02188017` - Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)	Phase 4
Recruiting	`NCT06113991` - Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
Completed	`NCT01169038` - Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis	Phase 1
Completed	`NCT03824392` - Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis	Phase 1/Phase 2